

Anti-neuroinflammatory asarone derivatives from the rhizomes of *Acorus tatarinowii*

Da-Peng Qin,^{‡a} Xiao-Lin Feng,^{‡a} Wei-Yang Zhang,^d Hao Gao,^a Xiao-Rui Cheng,^c Wen-Xia Zhou,^c Yang Yu,^{a, b*} and Xin-Sheng Yao^{a*}

^a *Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, P. R. China. E-mail: 1018yuyang@163.com; tyaoxs@jnu.edu.cn. Tel (Fax): +86-20-85221559*

^b *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P. R. China*


^c *Beijing Institute of Pharmacology and Toxicology, Tai Ping Road 27, Beijing 100850, P. R. China*

^d *State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, P. R. China*


List of Supporting Information

UV, IR, HR-ESI-MS spectrum and NMR spectra of 1	1
UV, IR, HR-ESI-MS spectrum and NMR spectra of 2	5
UV, IR, HR-ESI-MS spectrum and NMR spectra of 3	8
UV, IR, HR-ESI-MS spectrum and NMR spectra of 4	12
UV, IR, HR-ESI-MS spectrum and NMR spectra of 5	15
UV, IR, HR-ESI-MS spectrum and NMR spectra of 6	18
UV, IR, HR-ESI-MS spectrum and NMR spectra of 7	22
Chiral HPLC analytical chromatograms of compounds 2, 3, 7, 8, 14	26
Purity of compound.....	28
ECD spectrum of 8 and 14	28

UV spectrum of meso-asarolignan A (1) in CH₃OH.




IR (KBr disc) spectrum of meso-asarolignan A (1).



HR-ESI-MS spectrum of meso-asarolignan A (1).

Monoisotopic Mass, Even Electron Ions
 228 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass)
 Elements Used:
 C: 0-200 H: 0-1000 O: 0-200 Na: 0-1
 AT-E2-(5-6)-17
 20121126-11 109 (0.894) Cm (99:116)

1: TOF MS ES+
 8.77e+005




Minimum: -1.5
 Maximum: 5.0 5.0 50.0


Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf(%)	Formula
489.2094	489.2101	-0.7	-1.4	7.5	510.4	n/a	n/a	C ₂₄ H ₃₄ O ₉ Na

The 1D and 2D NMR spectra of meso-asarolignan A (1)


¹H NMR spectrum (AV-400, 400 MHz) of meso-asarolignan A (1) in CD₃OD




¹³C NMR spectrum (AV-400, 100 MHz) of *meso*-asarolignan A (1) in CD₃OD




HSQC spectrum (AV-400) of *meso*-asarolignan A (1) in CD₃OD




^1H - ^1H COSY spectrum (AV-400) of *meso*-asarolignan A (1) in CD_3OD




HMBC spectrum (AV-400) of *meso*-asarolignan A (1) in CD_3OD




UV spectrum of (\pm)-asarolignan B (2) in CH_3OH .



IR (KBr disc) spectrum of (\pm)-asarolignan B (2).




HR-ESI-MS spectrum of (\pm)-asarolignan B (2).




The 1D and 2D NMR spectra of (\pm)-asarolignan B (2)


^1H NMR spectrum (AV-400, 400 MHz) of (\pm)-asarolignan B (2) in CD_3OD




^{13}C NMR spectrum (AV-400, 100 MHz) of (\pm)-asarolignan B (2) in CD_3OD




HSQC spectrum (AV-400) of (±)-asarolignan B (2) in CD₃OD




HMBC spectrum(AV-400) of (±)-asarolignan B (2) in CD₃OD



UV spectrum of (\pm)-asarolignan C (3) in CH₃OH



IR (KBr disc) spectrum of (\pm)-asarolignan C (3).




HR-ESI-MS spectrum of (\pm)-asarolignan C (3).

AT-E2-61-10

20120707-13 125 (1.014) Cm (125)


1: TOF MS ES+
1.01e+005




Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
489.2103	489.2101	0.2	0.4	7.5	41.9	0.054	94.74	C ₂₄ H ₃₄ O ₉ Na
489.2125	489.2125	-2.2	-4.5	10.5	44.8	2.946	5.26	C ₂₆ H ₃₃ O ₉

The 1D and 2D NMR spectra of (\pm)-asarolignan C (3)


^1H NMR spectrum (AV-400, 400 MHz) of (\pm)-asarolignan C (3) in CD_3OD




^{13}C NMR spectrum (AV-400, 400 MHz) of (\pm)-asarolignan C (3) in CD_3OD




HSQC spectrum (AV-400) of (±)-asarolignan C (3) in CD₃OD




¹H-¹H COSY spectrum (AV-400) of (±)-asarolignan C (3) in CD₃OD




HMBC spectrum (AV-400) of (±)-asarolignan C (3) in CD₃OD



UV spectrum of (±)-asarolignan D (4) in CH₃OH




IR (KBr disc) spectrum of (±)-asarolignan D (4)



HR-ESI-MS spectrum of (±)-asarolignan D (4)

AT-E5H3-3
20130315-09 217 (1.758) Cm (207:222)

1: TOF MS ES+
1.14e+006




Minimum: -1.5
Maximum: 5.0 10.0 50.0


Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
471.2363	471.2359	0.4	0.8	7.5	570.6	0.040	96.04	C25 H36 O7 Na
471.2383	471.2383	-2.0	-4.2	10.5	573.7	3.235	3.94	C27 H35 O7
471.2324	471.2324	3.9	8.3	19.5	578.8	8.247	0.03	C34 H31 O2

The 1D and 2D NMR spectra of (±)-asarolignan D (4)


¹H NMR spectrum (AV-600, 600 MHz) of (±)-asarolignan D (4) in acetone-d₆




¹³C NMR spectrum (AV-600, 150 MHz) of (±)-asarolignan D (4) in acetone-*d*₆




HSQC spectrum (AV-600) of (±)-asarolignan D (4) in acetone-*d*₆




^1H - ^1H COSY spectrum (AV-600) of (\pm)-asarolignan D (4) in acetone- d_6




HMBC spectrum (AV-600) of (\pm)-asarolignan D (4) in acetone- d_6



UV spectrum of (\pm)-asarolignan E (5) in CH_3OH




IR (KBr disc) spectrum of (\pm)-asarolignan E (5)



HR-ESI-MS spectrum of (±)-asarolignan E (5)

AT-E5H4-1
20130315-14 212 (1.709) Cm (199:224)

1: TOF MS ES+
1.10e+006




Minimum: -1.5
Maximum: 50.0


Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
469.2203	469.2202	0.1	0.2	8.5	550.5	0.018	98.25	C25 H34 O7 Na
	469.2226	-2.3	-4.9	11.5	554.5	4.056	1.73	C27 H33 O7
	469.2168	3.5	7.5	20.5	559.1	8.627	0.02	C34 H29 O2

The 1D and 2D NMR spectra of (±)-asarolignan E (5)


¹H NMR spectrum (AV-400, 400 MHz) of (±)-asarolignan E (5) in CD₃OD




¹³C NMR spectrum (AV-400, 100 MHz) of (±)-asarolignan E (5) in CD₃OD




HSQC spectrum (AV-400) of (±)-asarolignan E (5) in CD₃OD




¹H-¹H COSY spectrum (AV-400) of (±)-asarolignan E (5) in CD₃OD




HMBC spectrum (AV-400) of (±)-asarolignan E (5) in CD₃OD



UV spectrum of (±)-asarolignan F (6) in CH₃OH



IR (KBr disc) spectrum of (±)-asarolignan F (6)




HR-ESI-MS spectrum of (±)-asarolignan F (6)

X-E-14-2

20120304-7 221 (1.788) Cm (218:223)

1: TOF MS ES+
2.78e+006




Minimum:
Maximum:

5.0 10.0 -1.5
50.0


Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
469.2204	469.2202	0.2	0.4	8.5	26.5	0.015	98.51	C25 H34 O7 Na
	469.2226	-2.2	-4.7	11.5	30.7	4.216	1.48	C27 H33 O7
	469.2168	3.6	7.7	20.5	35.3	8.802	0.02	C34 H29 O2

The 1D and 2D NMR spectra of (±)-asarolignan F (6)


¹H NMR spectrum (AV-300, 300 MHz) of (±)-asarolignan F (6) in CD₃OD




^{13}C NMR spectrum (AV-300, 75 MHz) of (\pm)-asarolignan F (6) in CD_3OD




HSQC spectrum (AV-300) of (\pm)-asarolignan F (6) in CD_3OD




^1H - ^1H COSY spectrum (AV-300) of (\pm)-asarolignan F (6) in CD_3OD




HMBC spectrum (AV-300) of (\pm)-asarolignan F (6) in CD_3OD




UV spectrum of (\pm)-asarolignan G (7) in CH₃OH



IR (KBr disc) spectrum of (\pm)-asarolignan G (7)




HR-ESI-MS spectrum of (\pm)-asarolignan G (7)




The 1D and 2D NMR spectra of (\pm)-asarolignan G (7)


¹H NMR spectrum (AV-400, 400 MHz) of (\pm)-asarolignan G (7) in CD₃OD




¹³C NMR spectrum (AV-400, 100 MHz) of (\pm)-asarolignan G (7) in CD₃OD




^1H - ^1H COSY spectrum (AV-400) of (\pm)-asarolignan G (7) in CD_3OD




HSQC spectrum (AV-400) of (\pm)-asarolignan G (7) in CD_3OD




HMBC spectrum (AV-400) of (±)-asarolignan G (7) in CD₃OD




NOESY spectrum (AV-400) of (±)-asarolignan G (7) in CD₃OD




Chiral HPLC analytical chromatograms of compound 2, 3, 7, 8, 14




column, Lux Amylose-2 column (5 μm , 4.6 \times 250 mm, Phenomenex); mobile phase, MeCN/H₂O = 35:75; flow rate: 0.7 mL/min; UV detection at 280 nm; peak area of **2a:2b** = 1:1; **2a**, t_{R} = 10.1 min; **2b**, t_{R} = 11.0 min.




column, Lux Amylose-2 column (5 μ m, 4.6 \times 250 mm, Phenomenex); mobile phase, MeCN/H₂O = 3:7; flow rate: 0.7 mL/min; UV detection at 280 nm; peak area of **3a:3b** = 1:1; **3a**, t_R = 12.0 min; **3b**, t_R = 12.8 min.



column, Lux Amylose-2 column (5 μ m, 4.6 \times 250 mm, Phenomenex); mobile phase, MeCN/H₂O = 6:4; flow rate: 0.7 mL/min; UV detection at 280 nm; peak area of **7a:7b** = 1:1; **7a**, t_R = 11.5 min; **7b**, t_R = 12.8 min.



column, Lux Amylose-2 column (5 μ m, 4.6 \times 250 mm, Phenomenex); mobile phase, MeCN/H₂O = 4:6; flow rate: 0.7 mL/min; UV detection at 280 nm; peak area of **8a:8b** = 1:1; **8a**, t_R = 21.0 min; **8b**, t_R = 22.0 min.



column, Lux Amylose-2 column (5 μ m, 4.6 \times 250 mm, Phenomenex); mobile phase, MeCN/H₂O = 4:6; flow rate: 0.7 mL/min; UV detection at 280 nm; peak area of **14a:14b** = 1:1; **14a**, t_R = 12.1 min; **14b**, t_R = 13.0 min.

Purity of compound

Purity of all the compounds were determined by HPLC using UV detection (peak area percentage represents the purity of compound), 1, 96.1% (208 nm); 2, 96.4% (208 nm); 2a, 96.4% (280 nm); 2b, 99.0% (280 nm); 3, 97.1% (208 nm); 3a, 98.2% (280 nm); 3b, 98.3% (280 nm); 4, 97.3% (208 nm); 5, 98.2% (208 nm); 6, 95.3% (208 nm); 7, 97.4% (208 nm); 7a, 97.4% (280 nm); 7b, 98.8% (280 nm); 8, 98.2% (208 nm); 8a, 96.6% (280 nm); 8b, 97.4% (280 nm); 9, 95.2% (208 nm); 10, 94.7% (208 nm); 11, 98.9% (208 nm); 12, 96.3% (208 nm); 13, 90.1% (208 nm); 14, 96.7% (208 nm); 14a, 97.2% (280 nm); 14b, 95.1% (280 nm); 15, 97.2% (208 nm); 16, 97.7% (208 nm); 17, 98.7% (208 nm); 18, 97.8% (208 nm); 19, 95.8% (208 nm); 20, 97.3% (208 nm); 21, 96.3% (208 nm); 22, 97.8% (208 nm); 23, 97.7% (208 nm).

ECD spectrum of 8 and 14

